Human immunodeficiency virus infection

There are 109 papers on human immunodeficiency virus infection in aging research: 1 trial and 70 observational studies in people, 1 in animals, 1 in cells, 29 reviews.

Disease

109 papers study it26 more mention it82 findings

3 new papers in 30 daysSee all 135 papers on human immunodeficiency virus infection

At a glance

Unsuppressed HIV is linked with shorter lifespan in a study of women; human observational studies also link HIV with higher epigenetic age, lower bone density and greater comorbidity burden. Frailty associations differ with adjustment: a study finds an unadjusted association but no clear link after accounting for social and behavioral factors and comorbidities.

82 findings in 53 papers from 2016 to 2026, 8 of them since May 2026

“After the second dose, the geometric mean titer (GMT) of NAbs was lower in PLWH (46.9, 95% confidence interval [CI] 43.6-50.4) compared to HCs (58.2, 95% CI 53.4-63.5).”
Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort studyJournal of virology2025doi:10.1128/jvi.00688-25
  • Human trial1
  • Humans70
  • Animals1
  • Cells1
  • In silico3

Effects

34

Telomere length

downin humans3no changein humans1

3 studies
  1. Human immunodeficiency virus infection is linked with lower telomere length in humans (ART-naïve HIV-infected vs healthy controls) (P<0.01).

    “Both naïve (CD45RA+) and memory (CD45RO+) CD8 T cells in this population had significantly shorter telomere lengths (P<0.01) compared to the HC group.”

    HumansART-naïve HIV-infected vs healthy controlsCD8 T cellsmales

    Accelerated Aging of T-Cell Subsets Among ART-Naïve HIV-Infected Chinese Men Who have Sex with Men: A Case-Control Study

    Current HIV research

  2. Human immunodeficiency virus infection is linked with lower telomere length in humans (untreated HIV infection) (median -2.12%/year (IQR, -3.48% to -0.76%/year; P = .002)).

    “During untreated human immunodeficiency virus (HIV) infection (median observation, 7.7; interquartile range [IQR], 4.7-11] years), TL declined significantly (median -2.12%/year; IQR, -3.48% to -0.76%/year; P = .002).”

    Humansuntreated HIV infectionperipheral blood mononuclear cellsmedian 7.7 yearsn = 107

    Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years

    The Journal of infectious diseases

  3. Human immunodeficiency virus infection was not clearly linked with telomere length in humans (between T2 and T3) (201±48 at T2 vs. 186±27 kbp/genome at T3, p=0.244).

    “while no differences were observed between T2 and T3 (201±48 at T2 vs. 186±27 kbp/genome at T3, p=0.244).”

    Humansbetween T2 and T3peripheral blood

    Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion

    Aging

  4. Human immunodeficiency virus infection is linked with lower telomere length in humans (between pre-HIV (T1) and immediately post-HIV (T2)) (227±46 at T1 vs. 201±48 kbp/genome at T2, p=0.045).

    “Telomere length significantly decreased between T1 and T2 (227±46 at T1 vs. 201±48 kbp/genome at T2, p=0.045)”

    Humansbetween pre-HIV (T1) and immediately post-HIV (T2)peripheral blood

    Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion

    Aging

More on Telomere length

Frailty

upin humans1no changein humans1OR 1.24

2 studies
  1. Human immunodeficiency virus infection was not clearly linked with frailty in humans (adjusted for social and behavioral factors and comorbidities) (OR 1.24, 95% CI 0.84 to 1.81).

    “HIV was not significantly associated with prefrailty/frailty (odds ratio = 1.24; 95% confidence interval: = 0.84 to 1.81).”

    Humansadjusted for social and behavioral factors and comorbidities

    Brief Report: Frailty in Aging People Living With HIV: A Matched Controlled Study

    Journal of acquired immune deficiency syndromes (1999)

  2. Human immunodeficiency virus infection increases frailty in PLWH.

    “an increased burden of cardiovascular disease, metabolic and bone disorders, HIV-associated neurocognitive disorder (HAND), non-AIDS-defining cancers, frailty”

    Reviewin PLWH

    Ageing with HIV Clinical and Organisational Challenges of Care

    Journal of Education Health and Sport

Coronary endothelial function

downin humans2

2 studies
  1. Human immunodeficiency virus infection is linked with worse coronary endothelial function in response to isometric handgrip exercise (CSA -0.78% vs 9.07%; CBF 3.85% vs 26.38%).

    “CEF was significantly reduced in PLWH compared to controls despite absence of CAD.”

    Humansin response to isometric handgrip exercise

    Beyond the Periphery: Coronary Endothelial Dysfunction as a Distinct Marker of Cardiovascular Risk in HIV

    AHA Scientific Sessions 2025 abstract

  2. Human immunodeficiency virus infection is linked with worse coronary endothelial function in humans (compared with individuals without HIV) (significantly lower).

    “CEF was significantly lower in PWH as compared with individuals without HIV.”

    Humanscompared with individuals without HIV

    Coronary artery endothelial function and aging in people with HIV and HIV-negative individuals

    American journal of physiology. Heart and circulatory physiology

Epigenetic age

upin humans2

2 studies
  1. Human immunodeficiency virus infection is linked with higher epigenetic age in humans (+11.2 years).

    “DNAm age in HIV-positive individuals is, on average, 11.2 years higher than HIV study participants at baseline”

    Humansperipheral bloodmales

    Identification of HIV infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive, treatment-naive U.S. veterans

    AIDS (London, England)

  2. Human immunodeficiency virus infection increases epigenetic age in people with HIV.

    “Longitudinal studies now document how leukocyte telomere attrition and epigenetic aging may be accelerated in people with HIV (PWH)”

    Reviewin people with HIV

    Perspective: clinical relevance of epigenetic aging and HIV

    Epigenomics

More on Epigenetic age

Neutralizing antibodies

downin humans1

1 study
  1. Human immunodeficiency virus infection decreases neutralizing antibodies in humans (at 28 days after the second vaccination (T1)) (46.9 vs 58.2).

    “At 28 days after the second vaccination (T1), the GMT of NAbs was significantly lower in PLWH than in HCs (46.9 [95% CI 43.6–50.4] vs 58.2 [95% CI 53.4–63.5]; P < 0.001), although the seropositivity and seroconversion rates were similar (97.9% vs 100.0%).”

    Human trialat 28 days after the second vaccination (T1)6-month post-vaccination follow-up

    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study

    Journal of virology

  2. Human immunodeficiency virus infection decreases neutralizing antibodies in humans after second dose (GMT 46.9 (95% CI 43.6-50.4) vs 58.2 (95% CI 53.4-63.5)).

    “After the second dose, the geometric mean titer (GMT) of NAbs was lower in PLWH (46.9, 95% confidence interval [CI] 43.6-50.4) compared to HCs (58.2, 95% CI 53.4-63.5).”

    Human trialafter second dose

    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study

    Journal of virology

More on Neutralizing antibodies

Immune age

downin silico1

1 study
  1. Human immunodeficiency virus infection decreases immune age in silico (HIV infection) (delta Age < 0).

    “validation in an independent HIV cohort revealed a counter-intuitive "negative aging" phenomenon, where the predicted immune age was significantly lower than chronological age (delta Age less than 0).”

    In silicoHIV infection

    Estimating Immune Age from B-Cell Receptor Repertoire Using Machine Learning

    International Conference on Bioinformatics and Biomedical Technology (ICBBT)

More on Immune age

Mitochondrial mass

upin humans1

1 study
  1. Human immunodeficiency virus infection is linked with higher mitochondrial mass in both total and senescent-like CD4+ and CD8+ T cells in PWH.

    “PWH exhibited increased mitochondrial mass and membrane potential in both total and senescent-like CD4+ and CD8+ T cells, particularly in CD8+ T cells from older PWH”

    Humansin both total and senescent-like CD4+ and CD8+ T cells in PWHT cells

    Immune profile and mitochondrial alterations driven by age and HIV infection: Associations with T-cell senescence in people with HIV receiving suppressive antiretroviral therapy

    Virologica Sinica

More on Mitochondrial mass

CD57

upin humans1

1 study
  1. Human immunodeficiency virus infection is linked with higher CD57 in younger PWH compared to younger HIV-negative individuals.

    “younger PWH had an ageing-like CD4+ T-cell profile, with higher CD57, CX3CR1 and TIGIT expression than younger HIV-negative individuals”

    Humansin younger PWH compared to younger HIV-negative individualsCD4+ T cells

    Immune profile and mitochondrial alterations driven by age and HIV infection: Associations with T-cell senescence in people with HIV receiving suppressive antiretroviral therapy

    Virologica Sinica

More on CD57

Bone mineral density

downin humans1

1 study
  1. Human immunodeficiency virus infection is linked with lower bone mineral density in humans (HIV infection in older men) (-7.1% [-10.9; -3.2]%).

    “Men with HIV (MLWH) had lower radial total vBMD (-7.1% [-10.9; -3.2]%), trabecular vBMD (-11.3% [-16.9%; -5.6%]), and BSIc (-12.0% [-18.7%; -5.4]%) than HIV-negative men.”

    HumansHIV infection in older menradiusmalesn = 1,101

    Sex-specific bone architectural deficits among older adults living with HIV: a cross-sectional study from Zimbabwe

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Systemic endothelial function

no changein humans1

1 study
  1. Human immunodeficiency virus infection was not clearly linked with systemic endothelial function in humans (measured by EndoPAT) (2.07 vs 2.02, p = 0.85).

    “In contrast, there was no significant difference in RHI between PLWH and controls (mean RHI: 2.07 [SD 0.81] vs 2.02 [SD 0.70], p = 0.85).”

    Humansmeasured by EndoPAT

    Beyond the Periphery: Coronary Endothelial Dysfunction as a Distinct Marker of Cardiovascular Risk in HIV

    AHA Scientific Sessions 2025 abstract

All 34

Associations

30

Frailty

upin humans6OR 1.89

6 studies
  1. Human immunodeficiency virus infection is associated with frailty in humans (people living with HIV vs without HIV).

    “to report a personal history of cardiovascular diseases; and to be frail.”

    Humanspeople living with HIV vs without HIVn = 1,049

    Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV

    HIV medicine

  2. Human immunodeficiency virus infection is associated with frailty in humans (unadjusted) (OR 1.89, 95% CI 1.37 to 2.61).

    “HIV was associated with prefrailty/frailty [odds ratio = 1.89; 95% confidence interval = 1.37 to 2.61)”

    Humansunadjusted

    Brief Report: Frailty in Aging People Living With HIV: A Matched Controlled Study

    Journal of acquired immune deficiency syndromes (1999)

  3. Human immunodeficiency virus infection is associated with frailty in humans (compared with uninfected counterparts).

    “PLHIV are increasingly confronted with age-related comorbidities and geriatric syndromes, including frailty and polypharmacy, which occur at a higher prevalence and set in at an earlier age compared with their uninfected counterparts.”

    Reviewcompared with uninfected counterparts

    An overview of multimorbidity and polypharmacy in older people living with HIV

    Geriatrics & gerontology international

  4. Human immunodeficiency virus infection is associated with frailty in humans (HIV) (10.9% (95% CI, 8.1%-14.2%)).

    “The overall pooled prevalence of frailty and prefrailty was 10.9% (95% confidence interval [CI], 8.1%-14.2%) and 47.2% (95% CI, 40.1%-54.4%), respectively.”

    ReviewHIVn = 6,584

    Prevalence of Frailty and Prefrailty in People With Human Immunodeficiency Virus Aged 50 or Older: A Systematic Review and Meta-Analysis

    Open forum infectious diseases

  5. Human immunodeficiency virus infection raises the risk of frailty in HIV-infected individuals.

    “The clinical expression of the immunosenescence state is an increased prevalence of aging-related non-HIV associated comorbidities and a rising prevalence of frailty occurring earlier than in the general population.”

    Reviewin HIV-infected individuals

    HIV infection as a cause of accelerated aging and frailty

    Revista espanola de geriatria y gerontologia

  6. Human immunodeficiency virus infection is associated with frailty in people with HIV.

    “In addition, conditions such as geriatric syndromes including frailty are also seen at higher rates.”

    Reviewin people with HIV

    HIV and aging

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Cardiovascular disease

upin humans3downin humans1

4 studies
  1. Human immunodeficiency virus infection is associated with cardiovascular disease in humans (people living with HIV vs without HIV).

    “Compared with participants without HIV, those with HIV were more likely to be male; to report lower education levels and incomes; to be more sedentary; to use tobacco, recreational, and prescription drugs; to report a personal history of cardiovascular diseases; and to be frail.”

    Humanspeople living with HIV vs without HIVn = 1,049

    Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV

    HIV medicine

  2. Human immunodeficiency virus infection is linked with a lower risk of cardiovascular disease in humans (compared with controls).

    “whereas those of cardiovascular disease, heart failure, ischaemic stroke and hypertension were lower in PLWH.”

    Humanscompared with controls

    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea

    HIV medicine

  3. Human immunodeficiency virus infection raises the risk of cardiovascular disease in PLWH.

    “manifests as premature multimorbidity, an increased burden of cardiovascular disease”

    Reviewin PLWH

    Ageing with HIV Clinical and Organisational Challenges of Care

    Journal of Education Health and Sport

  4. Human immunodeficiency virus infection raises the risk of cardiovascular disease in people living with HIV.

    “It underscores the high risk of cardiovascular disease, insulin resistance, dyslipidemia, and lipodystrophy in people living with HIV.”

    Reviewin people living with HIV

    Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review

    Health science reports

More on Cardiovascular disease

Myocardial infarction

upin humans2

2 studies
  1. Human immunodeficiency virus infection raises the risk of myocardial infarction in humans (odds of MI (4.06)).

    “human immunodeficiency virus infection quadrupling odds of MI (4.06)”

    Review

    Non-traditional risk factors for myocardial infarction in adults under forty: A systematic review of emerging trends

    World journal of cardiology

  2. Human immunodeficiency virus infection raises the risk of myocardial infarction in people living with HIV (1.2-2-fold).

    “Epidemiological studies indicate that PWH have a 1.2-2-fold higher risk of myocardial infarction (MI) and other CVD events compared to HIV-negative individuals.”

    Reviewin people living with HIV

    Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications

    Pharmaceuticals (Basel, Switzerland)

More on Myocardial infarction

Mortality

upin humans2

2 studies
  1. Human immunodeficiency virus infection is linked with a higher risk of mortality in COVID-19 patients until age difference reached 6 years or more.

    “PLWH had a significantly higher odds of death compared to non-PLWH until age difference reached 6 years or more”

    Humansin COVID-19 patients until age difference reached 6 years or more

    Impact of HIV on COVID-19 Outcomes: A Propensity Score Matching Analysis with Varying Age Differences

    AIDS and behavior

  2. Human immunodeficiency virus infection is linked with a higher risk of mortality in humans (at early stage of HIV diagnosis).

    “The RR of death from PLWH has decreased with the calendar year, but showed a tendency to rise again after 2014 and was significant at the early stage of HIV diagnosis.”

    Humansat early stage of HIV diagnosis

    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea

    HIV medicine

Non-communicable disease

upin humans1

1 study
  1. Human immunodeficiency virus infection is associated with non-communicable disease in humans (vs. uninfected controls).

    “Relative risks (RRs) for NCDs in PLWH were higher than controls in younger age groups.”

    Humansvs. uninfected controls

    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea

    HIV medicine

  2. Human immunodeficiency virus infection is linked with a higher risk of non-communicable disease in humans (adjusted incidence rate ratios) (58.5% vs 36.4%).

    “58.5% of PLWH and 36.4% of the controls were diagnosed with at least one NCD.”

    Humansadjusted incidence rate ratios

    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea

    HIV medicine

More on Non-communicable disease

Multimorbidity burden

upin humans1

1 study
  1. Human immunodeficiency virus infection is associated with multimorbidity burden in humans (before and after COVID-19).

    “PWH consistently had a higher multimorbidity burden than PWoH, and this disparity widened after COVID-19”

    Humansbefore and after COVID-19

    Increasing Multimorbidity Burden After COVID-19 Infection Among People With and Without HIV in the United States: Insights From the National Clinical Cohort Collaborative (N3C)

    Open forum infectious diseases

Biological age

upin humans1

1 study
  1. Human immunodeficiency virus infection is associated with biological age in humans (compared to HIV-negative individuals) (5 to 7 years).

    “people living with HIV are approximately 5 to 7 years biologically older than HIV-negative individuals”

    Reviewcompared to HIV-negative individuals

    Epigenetic clocks and accelerated biological aging in people living with HIV: Emerging mechanisms and clinical implications

    Experimental gerontology

Multimorbidity

upin silico1

1 study
  1. Human immunodeficiency virus infection is associated with multimorbidity in people living with HIV.

    “more than one-quarter will live with at least three additional chronic conditions”

    In silicoin people living with HIVby 2034

    Forecasting multimorbidity in aging people with HIV using a microsimulation model

    Communications health

Frailty-related fracture

upin humans1

1 study
  1. Human immunodeficiency virus infection is linked with a higher risk of frailty-related fracture in humans (Medicaid beneficiaries).

    “Compared to beneficiaries without NADC or HIV, all groups had significantly higher age-specific incidence of fracture.”

    HumansMedicaid beneficiaries

    Incidence of frailty-related fracture among Medicaid beneficiaries living with HIV and cancer: A cohort study

    PloS one

More on Frailty-related fracture

Cellular senescence

upin humans1

1 study
  1. Human immunodeficiency virus infection is associated with cellular senescence in PWH receiving suppressive ART.

    “ageing and HIV infection were associated with T-cell remodelling, characterized by expanded late-differentiated phenotypes and reduced stem-like, homeostatic and costimulatory CD4+ and CD8+ T-cell subsets”

    Humansin PWH receiving suppressive ARTCD4+ and CD8+ T cells

    Immune profile and mitochondrial alterations driven by age and HIV infection: Associations with T-cell senescence in people with HIV receiving suppressive antiretroviral therapy

    Virologica Sinica

More on Cellular senescence

All 30

Trial sponsors

Funding

1 grant since 2016

Gouvernement du Canada | Canadian Institutes of Health ResearchCA$1.5K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 6Jan 2026: 2Feb 2026: 4Mar 2026: 3Apr 2026: 2May 2026: 5Jun 2026: 1Jul 2026: 2Aug 2026: 1Sep 2026: 7Oct 2026: 2Nov 2026: 035 papers in 12 months

See all 135 papers on human immunodeficiency virus infection